CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Their core work

CNIC is Spain's premier cardiovascular research center, conducting fundamental and translational research on heart disease, vascular biology, and cardiac regeneration. They run clinical trials (such as the SECURE polypill trial for secondary cardiovascular prevention), develop advanced cardiac imaging techniques, and investigate the molecular mechanisms behind heart failure, cardiomyopathy, and atherosclerosis. Increasingly, they bridge cardiovascular and cancer research through their cardio-oncology program, studying how cancer treatments damage the heart and developing mitochondria-targeted therapies to prevent it.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), CNIC focused on classical cardiovascular research — clinical trials for secondary prevention (SECURE polypill), epigenetic regulation of cardiac aging (YOUNGatHEART), and vascular remodeling (MERC). From 2019 onward, a clear pivot emerged toward cardio-oncology (MATRIX, RESILIENCE), immunometabolism (STIMULATE, MY MITOCOMPLEX), and heart regeneration (REANIMA, TransReg). The recent period also shows growing integration of computational methods — machine learning for cardiac diagnostics (MAESTRIA) and advanced imaging (4DHeart, BRAV3).

CNIC is converging cardiovascular, oncology, and immunology research, positioning itself as a leader in cardio-oncology and mitochondrial medicine — fields expected to grow significantly as cancer survivorship increases.

How they like to work

CNIC leads more often than it follows: 17 of 30 projects were coordinated, including most of their ERC grants and several multi-partner RIA projects. They operate across a broad network of 171 unique partners in 25 countries, indicating they are a hub organization rather than a closed-loop collaborator. Their mix of large consortia (MAESTRIA, REANIMA) and smaller focused grants (MSCA fellowships, ERC) suggests they are comfortable both directing large teams and hosting individual researchers.

CNIC has collaborated with 171 unique partners across 25 countries, building one of the denser cardiovascular research networks in Europe. Their partnerships span Western Europe broadly, with particular strength in pan-European clinical and basic research consortia.

What sets them apart

CNIC is one of very few European research centers that combines deep cardiovascular expertise with a rapidly growing cardio-oncology program — a field where few institutes have the dual competency in heart and cancer biology. Their strong ERC track record (9 grants, including 2 Advanced and 7 Consolidator) signals that individual PIs are internationally competitive, not just the institution. For consortium builders, CNIC offers a rare combination: clinical trial infrastructure (SECURE), molecular biology depth (mitochondria, epigenetics), and advanced imaging — all under one roof in cardiovascular science.

Highlights from their portfolio

• SECURE
  Large-scale clinical trial on secondary cardiovascular prevention with a polypill — one of CNIC's most translational projects with direct patient impact.
• MATRIX
  Pioneering cardio-oncology project developing mitochondria-targeted therapies to protect the heart from cancer treatment damage — a fast-growing medical need.
• ProtMechanics-Live
  Largest single grant (EUR 2M ERC Advanced), investigating protein mechanics in cardiomyocytes — fundamental research with potential to redefine understanding of cardiomyopathy.